Analysis of the IMvigor210, a large phase 2 trial that investigated efficacy and safety of anti-PD-L1 antibody atezolizumab in bladder cancer, revealed that the levels of IGF2BP3 were notably elevated in the individuals who showed positive response (complete response/partial response) in contrast to those who did not respond (stable disease/progressive disease) (Fig. 7Q). This evidence concerns the gene CD274 and urinary bladder carcinoma.